Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Oxaliplatin is a key chemotherapy drug for colorectal and gastrointestinal cancers.
• Tumor resistance to oxaliplatin limits its clinical efficacy.
• The role of specific oxaliplatin transporters in treatment response is not fully understood.

Purpose of the Study:

• To investigate the association between oxaliplatin transporter gene expression and patient response to oxaliplatin.
• To experimentally validate the role of identified transporters, specifically MRP2, in gastrointestinal cancer models.
• To explore potential therapeutic strategies targeting MRP2 to overcome oxaliplatin resistance.

Main Methods:

• Clinical analysis of 18 candidate oxaliplatin transporter genes in colorectal cancer patient tumors.
• Experimental validation using human gastrointestinal cancer cell lines (HepG2, PANC-1, HEK293) with varying MRP2 expression.
• In vivo studies using mouse xenograft models treated with oxaliplatin and MRP2 inhibitors (myricetin, siRNA).

Main Results:

• MRP2 was the sole significantly differentially expressed transporter gene between responders and non-responders to FOLFOX chemotherapy.
• Overexpression of MRP2 reduced oxaliplatin accumulation and cytotoxicity in cancer cells.
• Inhibition of MRP2 (using myricetin or siRNA) restored oxaliplatin sensitivity, and concurrent myricetin treatment sensitized tumors in mice.

Conclusions:

• MRP2 plays a critical role in limiting oxaliplatin accumulation and efficacy in human gastrointestinal cancers.
• Measuring tumor MRP2 expression could help select patients for oxaliplatin-based therapies.
• Combining oxaliplatin with MRP2 inhibitors presents a potential strategy to enhance treatment outcomes.